The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)

• Status: Withdrawn
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt® will demonstrate positive hemodynamic effects. The clinical significance of this will be investigated by examining the ophthalmic and short posterior ciliary arteries to determine the blood supply to the optic nerve head, the site of damage in glaucoma

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Meir Medical Center
• Treatments: Dorzolamide; Latanoprost; Maleic acid; Timolol

Criteria

Inclusion Criteria:

1. 18 years of age or greater.

2. Patient signed an informed consent agreement.

3. Corrected visual acuity of 6/12 or better:

4. Characteristic glaucomatous visual-field loss and optic nerve head damage in one or both eyes.

5. Either IOP measurements ≥21 mmHg in the 3 months prior to study entry or IOP ≥ 21 mmHg at the end of the washout period

6. Patient on ≥1 IOP reducing agents. -

Exclusion Criteria:

1. Past history of ocular diseases (other than OAG / Cataract / Refractive error).

2. Past history of orbital/ocular surgery or trauma.

3. Receiving ≥ 3 IOP reducing agents.

4. Receiving agents known to produce significant cardiovascular, respiratory, renal or hepatic side effects.

5. Personal history of respiratory disease such as asthma, emphysema or other chronic obstructive pulmonary disease.

6. Personal history of congestive heart failure.

7. Personal history of bradycardia or 2nd and 3rd degree AV block.

8. Known allergy to sulfa.

9. Women who are pregnant or nursing.

10. Women who of child bearing age who are planning to become pregnant within one month after study completion.

11. Receiving Levitra, Viagra, Cialis or other erectile dysfunction drugs.